Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). (July 2017)

• Record Type: Journal Article
• Authors: Kerbrat, Pierre; Desmoulins, Isabelle; Roca, Lise; Levy, Christelle; Lortholary, Alain; Marre, Alain; Delva, Rémy; Rios, Maria; Viens, Patrice; Brain, Étienne; Serin, Daniel; Edel, Magali; Debled, Marc; Campone, Mario; Mourret-Reynier, Marie-Ange; Bachelot, Thomas; Foucher-Goudier, Marie-Josèphe; Asselain, Bernard; Lemonnier, Jérôme; Martin, Anne-Laure; Roché, Henri
• Is Part Of: European journal of cancer. Volume 79(2017)
• Page Start: 166
• Page End: 175
• Publication Date: 2017-07
• Subjects: Breast cancer -- Adjuvant chemotherapy -- Chemotherapy duration -- High-risk patients -- Node-negative -- FEC 100; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.03.004
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Purpose: Optimal duration of adjuvant chemotherapy in the treatment of early-stage breast cancer remained to be investigated rigorously for the standard regimens in widespread use in North America (doxorubicin/cyclophosphamide, AC) and Europe (5-fluorouracil/epirubicin/cyclophosphamide, FEC). Whether six cycles of FEC 100 present an advantage, or not, compared with only four cycles was tested directly in a phase III prospective multicentre trial. Patients and methods: Between 2002 and 2006, 1515 women between 18 and 65°years of age, with node negative N(−) high-risk early-stage breast cancer, were included in the study following breast surgery and axillary lymph node dissection or procedure by sentinel node technique. Inclusion in the study required tumour size T ≥ 1 cm and at least one of the high-risk factors: T > 2 cm, negative oestrogen receptor/progesterone receptor (ER– and PR–), Scarff-Bloom-Richardson (SBR) grade II or III and age ≤ 35°years. Patients were randomly assigned to either six FEC 100 (Arm A) or four FEC 100 (Arm B). The trial was powered to detect an absolute difference ≥6% in disease-free survival (DFS) at 5°years. Results: At 6.1°years median follow-up, with 91 (12%) events recorded in Arm A versus 106 (14%) in Arm B, no statistically significant risk increase was associated with four versus six FEC 100: DFS (hazard ratio (HR) = 1.18; CI 95% [0.89–1.56], P = .24) and overall survival (OS) (HR = 1.39; CI 95% [0.91–2.13], P = .12). Conclusion: Differences in chemotherapy duration did not induce notably different outcomes in our cohort of high-risk patients. Clinical trial registry number: NCT00055679, Agence National de Sécurité du Médicament (ANSM) – France. Highlights: 1516 high-risk breast cancer patients were randomised in 58 investigation centres. DFS rate at 5° years was 88.4% (4 FEC 100) versus 92.1% (6 FEC 100), HR = 1.18, P = .24. Grade 3 and 4 neutropenia were significantly more frequent with 6 FEC 100. The results suggest a trend toward better DFS and OS in the 6 FEC 100 arm. Assessment of high-risk patients must be more accurately defined.